The inflammasome is a critical immune complex that activates IL-1 driven inflammation in response to pathogen-and danger-associated signals. Nod-like receptor protein-1 (NLRP1) is a widely expressed inflammasome sensor. Inherited gain-of-function mutations in NLRP1 cause a spectrum of human Mendelian diseases, including systemic autoimmunity and skin cancer susceptibility. However, its endogenous regulation and its cognate ligands are still unknown. Here we apply a proteomics screen to identify dipeptidyl dipeptidase, DPP9 as a novel interacting partner and a specific endogenous inhibitor of NLRP1 inflammasome in diverse primary cell types from human and mice.
INTRODUCTION
The innate immune system exploits a large array of pattern-recognition receptors to detect pathogen-or danger-associated molecules to initiate a protective immune response (Janeway and Medzhitov, 2002) . A subset of immune sensor proteins belong to the Nod-like receptor protein (NLR) family and function as sensors for the inflammasome complex, a conserved macro-molecular platform that governs inflammation driven by the interleukin-1 family of cytokines. The mammalian inflammasome complex minimally consists of an NLR sensor, the adaptor protein ASC and the effector inflammatory caspase, caspase-1 (Davis et al., 2011; Martinon et al., 2002; Tschopp et al., 2003) . Upon ligand engagement by NLR sensors, the inflammasome complex initiates a distinct form of inflammatory cell death known as 'pyroptosis'. The distinguishing features and mediators of inflammasome-driven pyroptosis have been defined at the molecular level and include: 'prionoid-like' assembly of ASC (Lu et al., 2014) , proteolytic activation of caspase-1, processing of pro-IL-1B and pro-IL-18 into their respective bioactive mature forms, extracellular secretion of mature IL-1B and IL-18 (Martinon et al., 2002) , and lytic cell death following GSDMD-mediated membrane disruption (Kayagaki et al., 2015; Shi et al., 2015) . In concert with other innate immune pathways, the inflammasome plays an important role in immune defense against bacterial and viral infections (Lamkanfi and Dixit, 2011; Lamkanfi et al., 2007) , as demonstrated in the increased pathogen susceptibility in a variety of inflammasome knockout animal models.
In addition to robust, accurate and sensitive sensing of infection-or danger-related triggers, NLR proteins must avoid spontaneous and aberrant activation of 'sterile inflammation', which can lead to host tissue damage. Recent work has revealed that the Xu et al., 2014) . The in vivo importance of this regulatory network in preventing pathological inflammation is illustrated by a group 4 of Mendelian genetic diseases caused by mutations in inflammasome components. Most of the inflammasome-related disorders are caused by germline mutations in NLR sensor proteins or their negative regulators, resulting in unprovoked periodic fever and macrophage/monocyte activation caused by constitutive and persistent inflammasome activation (Kastner et al., 2010; Moghaddas and Masters, 2015) . In addition, dysregulation of NLR-driven inflammasome response has also been implicated in non-Mendelian diseases such as cancer, auto-immune and neuro-degenerative diseases (Davis et al., 2011; Venegas et al., 2017) . Hence, there is an important need to gain a fuller molecular understanding of how various NLR proteins are maintained in the inactive state without compromising their ability to readily activate inflammation upon ligand engagement.
We and others have recently characterized a unique member of the NLR family, NLRP1.
Although NLRP1 was one of the first NLR proteins shown to function as an inflammasome sensor, its cognate ligands and endogenous regulation remain poorly understood in human cells. NLRP1 differs from other known NLR sensor proteins in several aspects.
Patients who have germline mutations in NLRP1 all experience early-onset epithelial hyperkeratosis/dykeratosis, particularly on palmoplantar skin and in the eyes, while classical signs of fever or auto-inflammation that define other inflammasome activation diseases are variable (Grandemange et al., 2017; Zhong et al., 2016) . This is partially explained by the high level of expression of NLRP1 in squamous epithelia as compared to other NLRs. In fact, NLRP1 is likely the only inflammasome sensor expressed in Here we report the identification of dipeptidyl peptidase, DPP9 as an evolutionarily conserved, endogenous interacting partner and inhibitor of NLRP1 in primary human and mouse cells. Inhibition of DPP9 via small molecule inhibitors of its peptidase activity, targeted mutations of its catalytic site and genetic deletion act as potent triggers for NLRP1-dependent inflammatory death, which proceeds via NLRP1 oligomerization, ASC speck assembly and IL-1 cleavage in a range of primary cell types. Mechanistically we identify NLRP1-FIIND as a self-sufficient DPP9 binding domain whose disruption by a patient-derived point mutation leads to spontaneous NLRP1 inflammasome activation without impacting NLRP1 auto-proteolysis. This likely explains the persistent sterile inflammation seen in in the auto-inflammatory/auto-immune syndrome, NAIAD. Our findings highlight an unprecedented peptidase-based regulatory checkpoint for an inflammasome sensor that could be of broad relevance in human immunity and inflammatory diseases.
RESULTS

Identification of DPP9 as a novel binding partner of full-length, auto-inhibited NLRP1
To search for novel proteins that are involved in NLRP1 regulation, we took advantage of our previous observation that full-length NLRP1 is minimally active when expressed in 293T cells whereas the NLRP1 auto-proteolytic fragment (a.a. 1214-1474) is constitutively active (Finger et al., 2012; Zhong et al., 2016) . We thus hypothesized that 293T cells might express additional unknown factors that interact with the regulatory domains of NLRP1 (PYD, NACHT, LRR and FIIND) to help maintain NLRP1 self-inhibition in the absence of its cognate ligands. To identify such factors, we performed immunoprecipitation (IP) of FLAG-tagged full-length NLRP1 expressed in 293T cells, with the constitutively active fragment as a negative control ( Figure 1A ). Direct protein staining of 6 the IP eluates following SDS-PAGE revealed a prominent band at ~100 kDa that copurified only with full length NLRP1, but not a.a. 1213-1474 ( Figure 1B ). Quantitative mass spec by isobaric labeling of the FLAG IP eluates identified this candidate interacting protein as the long isoform of dipeptidyl peptidase, DPP9 (Uniprot Accession Q86TI2-2) ( Figure 1C ). It was amongst the most enriched proteins that associated with full length NLRP1, but not with vector transfected cells, or cells expressing NLRP1 a.a. 1213-1474 or a.a. 1213-1373 (fold change >16, Figure S1A Figure 1G , lane 4, vs lane 5). These results suggest that DPP9 is a specific NLRP1 interacting partner and a candidate regulatory factor maintaining full-length NLRP1 self-inhibition.
DPP9 inhibition triggers NLRP1 oligomerization, ASC speck formation and inflammasome activation
The chemical biology of DPP-IV family of peptidases has been extensively investigated due to the prominence of DPP4 as an effective anti-diabetic drug target (Pratley and Salsali, 2007) , and a number of small molecule inhibitors for DPP9 have been developed (Yazbeck et al., 2009 ). In addition, DPP8/9 inhibitors have recently been suggested to 7 activate an atypical form of pyroptotic cell death that does not involve ASC or IL-1 cleavage, though the mechanism remains unclear Taabazuing et al., 2017) . This prompted to us to consider if the enzymatic inhibition of DPP9 could directly activate the NLRP1 inflammasome. To test this, we reconstituted the NLRP1 inflammasome in a 293T reporter cell line that stably expressed GFP-tagged inflammasome adaptor, ASC (293T-ASC-GFP). When NLRP1-expressing 293T-ASC-GFP cells were treated with a pan-DPP-IV inhibitor, Talabostat (0.3 μM) or a specific DPP8/9 inhibitor 1G244 (10 μM), more than 70% of the cells formed large ASC-GFP specks that represented activated, assembled inflammasome complexes (Figure 2A To test this hypothesis and further probe the mechanism of how DPP9 inhibition might directly activate NLRP1 as an inflammasome sensor, we examined the monomer-tooligomer transition of NLRP1. Previously we established that NLRP1 activation requires an obligatory oligomerization step that is regulated by its N-terminal domains including PYD, NACHT and LRR. Human germline mutations in these domains, such as p.M77T 8 ( Figure 2B ,C) result in constitutive NLRP1 oligomer formation and cause aberrant inflammasome activation seen in patients (Zhong et al., 2016) . When NLRP1 expressing cells were treated with Talabostat, a substantial amount of NLRP1 underwent oligomerization into ~1 MDa high molecular weight species as detected by Blue-Native PAGE, while the total level of NLRP1 remained unchanged ( Figure 2D , SDS-PAGE, lane 2 vs.1 and lane 4 vs. 3). As this occurred in the absence of ASC, these results suggest that DPP9 exerts its inhibitory effect directly on NLRP1 by preventing its transition from inactive monomers to active oligomers. NLRP1 auto-cleavage generates an active Cterminal fragment, a.a. 1213-1474 ( Figure 1A ). We noted that this creates a potential DPP9 processing site with a proline residue at the P2 position. In the mass spec analysis of full-length NLRP1 immuno-purified from 293T cells, we readily detected tryptic peptides spanning and beginning at the auto-cleavage junction, which correspond to the uncleaved and auto-cleaved forms of NLRP1. However, we did not observe peptides that were consistent with DPP9 processing (i.e. starting at a.a. L1215), suggesting that NLRP1 might not be a direct enzymatic substrate of DPP9 ( Figure S2A ). We also confirmed that Talabostat did not engage NLRP1 itself using a cellular thermoshift assay ( Figure S2B ).
To rule out potential off-target effects of these chemical inhibitors, we exploited previous biochemical findings that DPP-IV family enzymes, including DPP9 are obligate dimers.
As a result, enzymatic dead mutants can function as dominant negative inhibitors upon overexpression, likely by sequestering the wild-type subunits (Tang et al., 2011) . The conserved 'catalytic triad' residues (S759, H869 and D837) were individually mutated to alanine to generate three dominant negative DPP9 constructs. When expressed in NLRP1 reconstituted 293T-ASC-GFP reporter cells, each of the catalytic triad mutant resulted in >60% of the cells forming ASC-GFP specks similar to Talabostat ( Figure 2E , red bars), while wild-type DPP9 showed the opposite effect-by suppressing the low basal level of ASC-GFP speck formation in wild-type NLRP1 expressing cells ( Figure 2E , gray bar). This was corroborated by direct visualization of ASC-GFP polymerization after covalent crosslinking with DSS ( Figure 2F , lanes 4 and 5 vs lane 1). These results offer orthogonal evidence that inhibition of the endogenous DPP9 enzyme triggers NLRP1 activation. To prove genetically that DPP9 is required to maintain NLRP1 in the inactive 9 state, we generated DPP9 KO 293T-ASC-GFP cells using CRISPR/Cas9 ( Figure 2G , lanes 1-4 vs. [5] [6] [7] [8] . In two independent clones, we observed a significantly higher percentage of cells forming ASC-GFP specks upon NLRP1 expression ( Figure 2H Partial knockdown of endogenous DPP8 caused a further increase in the percentage of cells forming ASC-GFP specks ( Figure 2H , red bars). Taken together with data from acute DPP9 inhibition, these findings establish that DPP9 functions as a novel and cognate inhibitor of NLRP1. In the absence of any trigger, DPP9 enzymatic activity acts as a 'brake' against aberrant NLRP1-inflammasome activation.
DPP9 inhibition leads to NLRP1-dependent pyroptosis via ASC oligomerization,
caspase-1 activation and mature IL-1 secretion
We next investigated the effect of DPP9 on NLRP1 in two primary human cell types that are of direct relevance to NLRP1-associated auto-inflammatory diseases: skin keratinocytes and freshly isolated peripheral blood mononuclear cells (PBMCs). While PBMCs express a number NLR sensors including NLRP1, we and others have recently established that NLRP1, rather than NLRP3 is the most prominent, if not the only inflammasome sensor expressed in resting human primary and immortalized, nontransformed keratinocytes (Zhong et al., 2016) . This provides a unique system to directly and specifically investigate the regulation of NLRP1 without impinging upon other NLR sensors such as NLRP3. Both keratinocytes and PBMCs secreted large amounts of mature IL-1B into the culture medium upon Talabostat treatment (3-30 μM) ( Figure   3A , >1000 fold). In PBMCs isolated from two out of three donors, the amount of IL-1B secretion after Talabostat treatment exceeded that elicited by 1 μg/ml of LPS ( Figure S3A Figure S3D ), while the only other cytokine that demonstrated a synergistic effect (>2 fold increase) was IL-1A, whose secretion also requires inflammasome activation in certain contexts (Gross et al., 2012) . These data support the notion that DPP9 inhibition might be a highly specific trigger for an IL-1 driven inflammatory response in diverse primary cell types. Given our biochemical findings on reconstituted NLRP1 inflammasome, we further postulated that DPP9 inhibition specifically acts upstream of and must require NLRP1 and ASC for pyroptosis induction. To test this genetically, immortalized keratinocytes were pre-treated with siRNAs for three days before DPP9 inhibition for 16 hours. siRNAs against NLRP3, which is not expressed in keratinocytes (RNAseq FKPM<1, EnCODE) was included as a negative control. Effective protein depletion (>70%) was observed at Day 4 ( Figure 3I , top). In contrast to untransfected and siNLRP3 treated keratinocytes, NLRP1-depleted keratinocytes failed to undergo ASC polymerization as measured by DSS crosslinking (Figure 3I Figure S3F ), in comparison to untransfected and siNLRP3treated controls. Similar results were obtained using 1G244, a more specific but less potent DPP8/9 inhibitor ( Figure 3J ). Furthermore, CRISPR/Cas9-mediated disruption of the NLRP1 and PYCARD (encoding ASC) loci abrogated IL-1B secretion following Talabostat treatment ( Figure 3J ). Together, these results provide genetic evidence that DPP9 inhibition specifically activates the NLRP1 inflammasome and IL-1 driven inflammation in primary, untransformed human cells in a manner that requires ASC and 12 caspase-1. We further took advantage of a suite of inflammasome KO murine models to investigate if DPP8/9 inhibition plays an evolutionarily conserved role as an NLRP1 inflammasome inhibitor, despite the divergence of NLRP1 genetic and protein structure.
Using primary bone marrow derived macrophages (BMDMs), we found that genetic ablation of all Nlrp1 isoforms (including Nlrp1a,b and c) and Figure 4A ); however, one mutation p.P1214R found in an NAIAD patient 13 is situated in the C-terminal auto-proteolytic fragment, a.a. 1213-1474, which is responsible for inflammasome activation ( Figure 4A ). Its pathogenic mechanism therefore remains unclear. To test if this mutation impacts the inhibitory effect DPP9 on NLRP1, we first carried out deletional mapping to identify the minimal DPP9 binding domain on NLRP1 ( Figure 4B ). NLRP1 shows a highly modular structure, and progressive removal of each NLRP1 domain revealed that PYD, NACHT, LRR and CARD were dispensable for DPP9 binding ( Figure 4B , Figure 4C, lanes 6, 8, 9 ), while the intact FIIND domain (a.a. 986-1373) was required ( Figure 4B, Figure 4C Although the NAIAD mutation, P1214R is found adjacent to the FIIND cleavage site, we did not observe any appreciable difference in its degree of auto-cleavage relative to wildtype NLRP1 when expressed in 293T cells ( Figure 4E ). However, it did potently abrogate NLRP1 auto-inhibition and led to constitutive inflammasome activation in both 293T-ASC-GFP reporter cells ( Figure 4F ) and in immortalized human keratinocytes, as measured by IL-1B secretion ( Figure 4G ), in agreement with its causal role in NAIAD. Next, we tested the ability of P1214R to interact with endogenous DPP9 by co-IP. When expressed at similar levels, P1214R completely abrogated the ability of full length NLRP1 or NLRP1- Hence, the loss of DPP9-NLRP1 interaction by a single point mutation in NLRP1-FIIND is sufficient to disrupt NLRP1 self-inhibition and lead to pathological auto-inflammation in vivo as observed in NAIAD patients. 14 
DISCUSSION
Although NLRP1 was one of the first inflammasome sensors to be identified, its function in innate immunity and human inflammatory conditions has not been characterized in detail, presumably due to the lack of knowledge on its endogenous regulation and ligand Most importantly, we have delineated the mechanism by which DPP9 regulates NLRP1
activation. Our biochemical analysis shows that the DPP9 directly binds to NLRP1 via the Taken together, we propose that NLRP1 acts as a sensor for a 'homeostasis-altering molecular process' (HAMP) (Liston and Masters, 2017) involving alterations of DPP9 enzymatic activity. DPP9 might be suppressed during infection by a foreign pathogen that is yet to be identified. This could be an integral part of the host immune response or elicited by a pathogen effector that seeks to manipulate host cell physiology to facilitate infection. In this case, alterations of DPP9 enzymatic activity would alert the host to a loss of cellular homeostasis, and this process therefore requires constant monitoring by a dedicated sensor-NLRP1. In the absence of any trigger, enzymatically active DPP9 'locks' NLRP1 in the monomeric state to prevent aberrant activation. This is conceptually akin to the recently discovered mechanism by which another inflammasome sensor, Pyrin monitors Rho-GTPase for the presence of unusual post-translational modifications deposited by secreted bacterial toxins (Xu et al., 2014) . We postulate that this HAMP detection system might allow human cells to mount a productive, inflammasome-driven immune response for rapid pathogen clearance. When its regulation is disrupted by germline mutations in NLRP1 or chemical/dominant-negative DPP9 inhibition, NLRP1 rapidly oligomerizes and assembles the inflammasome complex consisting of ASC and caspase-1 that initiates IL-1 driven inflammation. Our work provides the foundation for additional investigation of the biochemical nature of this novel immune regulatory mechanism and implicate DPP9 as a potential regulator in human inflammatory disorders. 16 
Materials and methods
Cell culture 293Ts (laboratory stock) was cultured in DMEM supplemented with 10% fetal bovine serum (FBS) without antibiotics. Immortalized keratinocytes (N/TERT-1) were cultured in Keratinocyte Serum-free media with bovine pituary extract, EGF in the presence of 0.3mM CaCl2. PBMCs were obtained from donor using Ficoll and cultured in RPMI media with 10% FBS. Primary human keratinocytes were cultured using methods described by Rheinwald and Green (Rheinwald and Green, 1975) . BMDM were prepared from the 
Immunoprecipitation and mass spectrometry
Small scale immunoprecipitations were carried out by incubating overnight 0.5 mg total cell lysate prepared in 1xTBS-NP40 buffer (20mM Tris-HCl, 150 mM NaCl, 0.5% NP-40) and 10 μl of anti-FLAG-M2 agarose resin (Sigma-Aldrich) in 300~500 μl total volume.
Bound proteins were eluted in 1x Laemmli's buffer at 95°C for 5 minutes.
For mass spectrometry, approximately 10 8 transfected 293T cells were lysed in 3 ml 1xTBS-NP40 buffer and 100 μl anti-FLAG M2 agaorase beads were used for immunoprecipitation and directed subjected to trypsin digestion after washes in lysis buffer. Equal amount of peptides was taken for TMT isobaric tag (Thermo) labeling. 
Plasmid transfection and lentiviral transduction
Blue-Native and SDS-PAGE
Blue-Native PAGE was carried out using the Native-PAGE system (ThermoFisher) with 10-20 μg total cell lysate followed by dry transfer (TurboBlot, Bio-rad) and Western blot.
SDS-PAGE was carried out using pre-cast TGX 4-20% gels (Bio-rad). 
CRISPR/Cas9 gene editing
Measurement of cell death in PBMCs
After harvesting supernatants from PBMCs, the remaining cell pellets were used for quantification of cell death. Cells were washed in PBS, resuspended and incubated for 
